Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use.
作者信息
Impicciatore P, Choonara I
机构信息
Academic Division of Child Health, (University of Nottingham), Derbyshire Children's Hospital, Derby, UK.
出版信息
Br J Clin Pharmacol. 1999 Jul;48(1):15-8. doi: 10.1046/j.1365-2125.1999.00981.x.
Abstract
AIMS
To evaluate the activity of the European Medicines Evaluation Agency with regard to the registration for paediatric use of new medicines granted a marketing authorization.
METHODS
European Public Assessment Reports published on the Internet from January 95 until April 98 have been analysed using the browser Microsoft Explorer and the software Adobe Acrobat Reader.
RESULTS
Of the 45 new substances licensed since January 95, 29 (64%) were of possible use in children but only 10 were licensed for paediatric use. For the 19 drugs of possible use in children, but not approved for such a use, in nine instances (47%) their summary of product characteristics reported that their use in children has not been established.
CONCLUSIONS
A change of practice by pharmaceutical companies and regulatory authorities is imperative so that children are not precluded from having the same rights to medicines as adults.
摘要
相似文献
1
Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use.
Br J Clin Pharmacol. 1999 Jul;48(1):15-8. doi: 10.1046/j.1365-2125.1999.00981.x.
2
Lack of effect of the European guidance on clinical investigation of medicines in children.
Acta Paediatr. 2002;91(11):1233-8. doi: 10.1080/080352502320777487.
3
Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Eur J Clin Pharmacol. 2002 Nov;58(8):495-500. doi: 10.1007/s00228-002-0511-0. Epub 2002 Sep 25.
4
Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years.
Eur J Clin Pharmacol. 2006 Nov;62(11):947-52. doi: 10.1007/s00228-006-0193-0. Epub 2006 Oct 5.
5
Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
PLoS Med. 2018 Mar 1;15(3):e1002520. doi: 10.1371/journal.pmed.1002520. eCollection 2018 Mar.
6
[Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Arch Pediatr. 2014 Oct;21(10):1129-38. doi: 10.1016/j.arcped.2014.07.011. Epub 2014 Aug 28.
7
Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.
Eur J Clin Pharmacol. 2010 Jan;66(1):39-48. doi: 10.1007/s00228-009-0756-y. Epub 2009 Nov 20.
8
Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
Paediatr Drugs. 2017 Dec;19(6):505-513. doi: 10.1007/s40272-017-0261-1.
9
Who are the PDCO?
Eur J Pediatr. 2014 Feb;173(2):233-5. doi: 10.1007/s00431-013-2096-2. Epub 2013 Aug 8.
10
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Milbank Q. 2020 Dec;98(4):1219-1256. doi: 10.1111/1468-0009.12476. Epub 2020 Oct 6.
引用本文的文献
1
Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994-2007.
Br J Clin Pharmacol. 2011 Jun;71(6):929-35. doi: 10.1111/j.1365-2125.2010.03881.x.
2
Public awareness and views on unlicensed use of medicines in children.
Br J Clin Pharmacol. 2008 Dec;66(6):838-45. doi: 10.1111/j.1365-2125.2008.03290.x.
3
Individual case safety reports in children in commonly used drug groups - signal detection.
BMC Clin Pharmacol. 2008 Mar 17;8:1. doi: 10.1186/1472-6904-8-1.
4
Drug related problems and off-label drug treatment in children as seen at a drug information centre.
Eur J Pediatr. 2007 Jun;166(6):527-32. doi: 10.1007/s00431-006-0385-8. Epub 2006 Dec 29.
5
Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years.
Eur J Clin Pharmacol. 2006 Nov;62(11):947-52. doi: 10.1007/s00228-006-0193-0. Epub 2006 Oct 5.
6
Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.
Br J Clin Pharmacol. 2007 Jan;63(1):85-91. doi: 10.1111/j.1365-2125.2006.02729.x. Epub 2006 Jul 26.
7
A major new initiative to improve treatment for children.
Arch Dis Child. 2006 Mar;91(3):212-3. doi: 10.1136/adc.2005.077073.
8
Changes in availability of paediatric medicines in Australia between 1998 and 2002.
Br J Clin Pharmacol. 2005 Jun;59(6):736-42. doi: 10.1111/j.1365-2125.2004.02211.x.
9
Effect of the pediatric exclusivity provision on children's access to medicines.
Br J Clin Pharmacol. 2005 Jun;59(6):730-5. doi: 10.1111/j.1365-2125.2005.02327.x.
10
A literature review on off-label drug use in children.
Eur J Pediatr. 2005 Sep;164(9):552-8. doi: 10.1007/s00431-005-1698-8. Epub 2005 May 24.
本文引用的文献
1
Secrecy and transparency of medicines licensing in the EU.
Lancet. 1998 Aug 8;352(9126):480-2. doi: 10.1016/S0140-6736(97)11282-X.
2
Licensing of medicines.
Arch Dis Child. 1998 May;78(5):402-3. doi: 10.1136/adc.78.5.402.
3
Unlicensed and off label drug use in paediatric wards: prospective study.
BMJ. 1998 Jan 31;316(7128):343-5. doi: 10.1136/bmj.316.7128.343.
4
Children have rights to medicines.
BMJ. 1997 Jul 5;315(7099):62. doi: 10.1136/bmj.315.7099.62a.
5
6
Is the "therapeutic orphan" about to be adopted?
Pediatrics. 1996 Jul;98(1):118-23.
7
The European Medicines Evaluation Agency.
BMJ. 1996 Feb 17;312(7028):394. doi: 10.1136/bmj.312.7028.394.
8
Use of "off-label" and unlicensed drugs in paediatric intensive care unit.
Lancet. 1996 Feb 24;347(9000):549-50.
9
Status of drug approval processes and regulation of medications for children.
Curr Opin Pediatr. 1995 Apr;7(2):195-8. doi: 10.1097/00008480-199504000-00014.
Zotero 插件